Harvard Bioscience (HBIO) Cash from Investing Activities (2010 - 2026)
Harvard Bioscience's (HBIO) quarterly Cash from Investing Activities came in at -$620000.0 in Q1 2026, up 9.22% year-on-year from -$567640.8 in Q1 2025, and down 3.51% on a QoQ basis from -$599000.0 in Q4 2025.
Harvard Bioscience (HBIO) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Harvard Bioscience (HBIO) has 17 years of Cash from Investing Activities data on file, last reported at -$620000.0 in Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 9.22% year-over-year to -$620000.0 in Q1 2026; TTM through Mar 2026 was -$1.8 million, a 0.11% change from a year earlier, with the FY2025 full-year figure at -$1.9 million, down 38.62% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$620000.0, down from -$599000.0 in the prior quarter.
- Over the last five years, Cash from Investing Activities for HBIO reached as high as $458000.0 in Q2 2024 and fell as low as -$1.1 million in Q3 2024.
- Historically, Cash from Investing Activities has averaged -$424470.6 across 5 years, with a median of -$442000.0 in 2022.
- Across the five-year window, Cash from Investing Activities sank 351.49% in 2023 and soared 173.28% in 2024, its largest moves.
- Year by year, Cash from Investing Activities stood at -$235000.0 in 2022, then sank by 351.49% to -$1.1 million in 2023, then jumped by 56.08% to -$466000.0 in 2024, then fell by 28.54% to -$599000.0 in 2025, then retreated by 3.51% to -$620000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were -$620000.0 in Q1 2026, -$599000.0 in Q4 2025, and -$348000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 126.59 Bn | 121.37 Bn | 1.96 Bn | -26.60 Mn |
| 2 | Becton Dickinson | 44.93 Bn | 44.11 Bn | 2.15 Bn | -139.00 Mn |
| 3 | Alcon | 32.92 Bn | 31.27 Bn | 1.53 Bn | -218.00 Mn |
| 4 | Medline | 32.85 Bn | 30.61 Bn | 1.84 Bn | -96.00 Mn |
| 5 | Resmed | 29.43 Bn | 27.77 Bn | 890.98 Mn | -58.03 Mn |
| 6 | West Pharmaceutical Services | 23.41 Bn | 22.97 Bn | 329.20 Mn | -43.20 Mn |
| 7 | Solventum | 14.08 Bn | 13.51 Bn | 1.10 Bn | -77.00 Mn |
| 8 | Cooper Companies | 13.79 Bn | 13.65 Bn | 735.40 Mn | -90.00 Mn |
| 9 | Align Technology | 12.04 Bn | 10.98 Bn | 736.59 Mn | -131.58 Mn |
| 10 | Harvard Bioscience | 27.26 Mn | 20.16 Mn | 12.24 Mn | -620,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -620,000.00 |
| Mar 31, 2026 | -620,000.00 |
| Dec 31, 2025 | -599,000.00 |
| Dec 31, 2025 | -599,000.00 |
| Sep 30, 2025 | -348,000.00 |
| Sep 30, 2025 | -348,000.00 |
| Jun 30, 2025 | -233,000.00 |
| Jun 30, 2025 | -233,000.00 |
| Mar 31, 2025 | -683,000.00 |
| Mar 31, 2025 | -683,000.00 |
| Dec 31, 2024 | -466,000.00 |
| Dec 31, 2024 | -466,000.00 |
| Sep 30, 2024 | -1.11 Mn |
| Sep 30, 2024 | -1.11 Mn |
| Jun 30, 2024 | 458,000.00 |
| Jun 30, 2024 | 458,000.00 |
| Mar 31, 2024 | -225,000.00 |
| Mar 31, 2024 | -225,000.00 |
| Dec 31, 2023 | -1.06 Mn |
| Dec 31, 2023 | -1.06 Mn |